Biopharmaceutical manufacturing involves a balancing act between the capacity of cell culture and downstream purification. Balancing the two has always been difficult because construction decisions ...

Argonaut’s Clinical Fill-Finish Capabilities to Complement Avid’s Upstream and Downstream Process Development and Biologics Manufacturing Services in Supporting Developers of Biologic Therapeutics ...

Under terms of the non-exclusive agreement, the companies will offer Avid’s upstream and downstream process development and drug substance manufacturing services in tandem with Argonaut’s ...

If a process is showing dramatic upstream improvements, it will likely be worth the expense to install more downstream capacity, and at the same time implement process improvements (changes!) even ...